Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 10/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 8/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13652991 | 0.85 | CDK8 (0.42) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL1013289 | 0.81 | ALDH1A1 (0.56) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL29397663 | 0.80 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL1011502 | 0.80 | MAPK14 (0.43) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL15007938 | 0.80 | GRN (0.43) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL31388014 | 0.80 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11GRN | |
| Hydrochloric Acid SCHEMBL1492473 | 0.80 | ALDH1A1 (0.55) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL1015406 | 0.80 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11GRN | |
| SCHEMBL31457163 | 0.80 | CYP1A2 (0.57) | OPRM1ALDH1A1MAPT | |
| SCHEMBL1814517 | 0.80 | CYP1A2 (0.57) | OPRM1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-07-19 | — | — | US | disclosed |
| US-8030311-B2 | Phenylacetamides suitable as protein kinase inhibitors | NOVARTIS AG (CH) | 2011-10-04 | — | — | US | disclosed |
| EP-1874770-B1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-09 | — | — | EP | disclosed |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2008-12-25 | — | — | US | disclosed |
| EP-1874770-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | Novartis Pharma AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006108640-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184561-A1 | PHENYLACETAMIDES SUITABLE AS PROTEIN KINASE INHIBITORS | MAP3K10, MAP3K20, MAP3K9 | MAPK14 81/4885MAPK13 161/4885MAPK12 122/4885 |
| US-20080319005-A1 | Phenylacetamides Suitable as Protein Kinase Inhibitors | MAP3K20, MAP3K10, MAP3K9 | MAPK14 80/4885MAPK13 148/4885MAPK12 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.